Capstone Investment Advisors
CRNX

Capstone Investment Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Capstone Investment Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
7,107
-1,905
-21% -$70.8K ﹤0.01% 1516
2026
Q1 		$327K Buy
+9,012
New +$403K ﹤0.01% 1333
2025
Q4 		– Sell
-6,678
Closed -$278K – 1679
2025
Q3 		$278K Buy
+6,678
New +$214K ﹤0.01% 1681

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's CRNX Position: Q2 2026 in Review

Capstone Investment Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 21% in Q2 2026, selling an estimated $70.8K and leaving 7,107 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Capstone Investment Advisors first reported a position in CRNX in Q3 2025 and has held it in 3 quarters since. The position peaked at $327K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Capstone Investment Advisors held 7,107 shares of Crinetics Pharmaceuticals worth $266K as of Q2 2026.
  • Capstone Investment Advisors sold 1,905 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $70.8K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1516 holding.
  • Capstone Investment Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Crinetics Pharmaceuticals position peaked at $327K in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.